Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis

BACKGROUND: Active inflammatory bowel disease increases the risk of adverse pregnancy outcomes. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). As a small molecule, tofacitinib is likely to cross the placental barrier; however, information...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahadevan, Uma, Dubinsky, Marla C, Su, Chinyu, Lawendy, Nervin, Jones, Thomas V, Marren, Amy, Zhang, Haiying, Graham, Daniela, Clowse, Megan E B, Feldman, Steven R, Baumgart, Daniel C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
IBD Live
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262193/
https://www.ncbi.nlm.nih.gov/pubmed/29982686
http://dx.doi.org/10.1093/ibd/izy160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262193/
https://www.ncbi.nlm.nih.gov/pubmed/29982686
http://dx.doi.org/10.1093/ibd/izy160

Ejemplares similares